Clinical Trials
10 trialsNCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT01468922 2022-07-01
Pazopanib and ARQ 197 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02138526 2020-10-19
DIET
Radboud University Medical Center
Phase 1 Completed
NCT00674024 2019-11-20
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00387205 2019-03-06
Study To Assess Long Term Safety Of Pazopanib
Novartis
Phase 1 Completed
NCT00861029 2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00992121 2017-11-13
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Phase 1 Completed
NCT01130623 2017-07-02
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn